Project Grant HT94252510763
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$551K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
This federal Project Grant award, totaling $431,750.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will support research conducted by the University of Houston System to investigate the role of H19X noncoding RNAs in the pathogenesis of myotonic dystrophy type I. The award duration is from December 1, 2024 to November 30, 2026. The Military Medical Research and Development program funds advanced biomedical...
The federal Project Grant award ID HT94252510342, totaling $405,341.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The award supports the use of proresolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy at the Children's Research Institute, a non-profit pediatric research organization in Washington, D.C. The award will fund advanced biomedical research and development focused...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
The U.S. Defense Health Agency awarded a $777,659 Project Grant to the Children's Research Institute in Washington, D.C. under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research to transform healthcare for military service members, veterans, and the public, with a focus on innovative research addressing critical health challenges. Specifically, the award will fund the "Use of ProResolution and Restorative Pharmacology...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This $1,599,997.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Illinois aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational investigations, focuses on innovative approaches to address critical health challenges across diverse medical domains such as cancer,...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to the University of California, Los Angeles (UCLA) to develop 3D-Bridge antisense oligonucleotides and a stem cell-targeting modality for skipping exons of Duchenne muscular dystrophy. The award period is from July 1, 2024 to June 30, 2026. Through this grant, UCLA will leverage its research and administrative capabilities to advance novel therapeutic...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The Defense Health Agency awarded a $974,043 Project Grant to Cedars-Sinai Medical Center under the Military Medical Research and Development (CFDA 12.420) program. The grant supports early cardiac biomarker research focused on inflammation and remodeling in Duchenne muscular dystrophy. This 4-year award, running from September 1, 2025 to August 31, 2029, will fund innovative biomedical investigations at Cedars-Sinai aimed at transforming healthcare for military service members and the broader...